Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFIC-9
jRCT2021210072Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab + oleclumab, Durvalumab + monalizumab and Durvalumab + placebo (3 arms). Primary endpoint: Progression-free survival. Started Feb 2021; status: active, not recruiting.
02
Drugs
durvalumaboleclumabmonalizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2021210072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210072.